Pharmacogenetic testing, which is used to classify how patients with major depressive disorder (MDD) metabolize medications, reduces adverse drug-gene interactions, new research shows. In a randomized ...
Most antidepressants are metabolized through the cytochrome P (CYP) 450 pathway; therefore, most drug metabolism genes on pharmacogenetic testing panels are related to CYP450 oxidase enzyme subunits.